CASE STUDY

Supporting Patient Access to Treatment

For the European Medicines Agency to maintain the Orphan Drug Designation, data was necessary to evaluate the use and access to mexiletine across Europe. There is limited data on the impact of and disrupted availability of mexiletine in the EU.

3

Situation

There are no dedicated support groups in Germany for an ultra-rare disease. It‘s not easy to find patients, they are undiagnosed or diagnosed but unaware of other families to connect with.

Our Solution

1

Creating a patient landing page that includes easy-to-understand information for affected families

2

Designing information materials to share with physicians and their patients

3

Simultaneously reaching out to several stakeholders, e.g.: physicians, therapists, patient organizations, and families to understand the care situation better

4

Joint dissemination of information through all relevant stakeholders and patient groups (including social media groups)

5

Support further contact with highly targeted social media advertising

Results

1

Obtaining important insights into the patient landscape and detection of relevant health care gaps

Back to all case studies